Yvonne McGrath
Chief Tech/Sci/R&D Officer at ITEOS THERAPEUTICS, INC.
Net worth: 422 840 $ as of 2024-03-30
Profile
Yvonne McGrath is currently the Chief Scientific Officer at iTeos Therapeutics, Inc. She previously worked as the Director & Chief Scientific Officer at Complix NV from 2014 to 2020 and as the Head-Development at Immunocore Holdings Plc from 2010 to 2014.
Dr. McGrath holds a doctorate degree from The University of Wales, which she obtained in 2000.
She also has an undergraduate degree from Queen's University Belfast.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
ITEOS THERAPEUTICS, INC.
0.09% | 2024-03-06 | 31,000 ( 0.09% ) | 422 840 $ | 2024-03-30 |
Yvonne McGrath active positions
| Companies | Position | Start |
|---|---|---|
| ITEOS THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2020-04-30 |
Former positions of Yvonne McGrath
| Companies | Position | End |
|---|---|---|
Complix NV
 Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Chief Tech/Sci/R&D Officer | 2020-03-31 |
| IMMUNOCORE HOLDINGS PLC | Corporate Officer/Principal | 2014-03-31 |
Training of Yvonne McGrath
| The University of Wales | Doctorate Degree |
| Queen’S University Belfast | Undergraduate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 2 |
|---|---|
| ITEOS THERAPEUTICS, INC. | Health Technology |
| IMMUNOCORE HOLDINGS PLC | Health Technology |
| Private companies | 1 |
|---|---|
Complix NV
Complix NV Pharmaceuticals: MajorHealth Technology Complix NVengages in the development of biopharmaceutical company developing Alphabodies, a pipeline of transformative protein therapeutics. The Company is currently focusing its internal research and development activities on oncology and autoimmune diseases. Its therapeutic Alphabodies focuses on the treatment of autoimmune diseases, such as rheumatoid arthritis, psoriasis and multiple sclerosis, and infectious diseases, and viral diseases such as influenza, HIV, and RSV. The company was founded by Mark Vaeck and Ignace Lasters in 2008 and is headquartered in Diepenbeek, Belgium. | Health Technology |
- Stock Market
- Insiders
- Yvonne McGrath
